- Home
- MYFW vs CRVS Comparison
MYFW vs CRVS Comparison
Compare MYFW & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYFW
- CRVS
- Stock Information
- Founded
- MYFW 2002
- CRVS 2014
- Country
- MYFW United States
- CRVS United States
- Employees
- MYFW N/A
- CRVS N/A
- Industry
- MYFW Major Banks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- MYFW Finance
- CRVS Health Care
- Exchange
- MYFW Nasdaq
- CRVS Nasdaq
- Market Cap
- MYFW 201.1M
- CRVS 305.4M
- IPO Year
- MYFW 2018
- CRVS 2016
- Fundamental
- Price
- MYFW $23.90
- CRVS $4.11
- Analyst Decision
- MYFW Buy
- CRVS Strong Buy
- Analyst Count
- MYFW 2
- CRVS 4
- Target Price
- MYFW $24.25
- CRVS $15.00
- AVG Volume (30 Days)
- MYFW 64.8K
- CRVS 1.1M
- Earning Date
- MYFW 07-24-2025
- CRVS 08-05-2025
- Dividend Yield
- MYFW N/A
- CRVS N/A
- EPS Growth
- MYFW 154.12
- CRVS N/A
- EPS
- MYFW 1.04
- CRVS N/A
- Revenue
- MYFW $91,514,000.00
- CRVS N/A
- Revenue This Year
- MYFW $17.24
- CRVS N/A
- Revenue Next Year
- MYFW $10.85
- CRVS N/A
- P/E Ratio
- MYFW $22.95
- CRVS N/A
- Revenue Growth
- MYFW 13.99
- CRVS N/A
- 52 Week Low
- MYFW $15.54
- CRVS $1.92
- 52 Week High
- MYFW $24.26
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- MYFW 72.14
- CRVS 53.94
- Support Level
- MYFW $23.10
- CRVS $3.79
- Resistance Level
- MYFW $23.54
- CRVS $4.31
- Average True Range (ATR)
- MYFW 0.67
- CRVS 0.29
- MACD
- MYFW 0.16
- CRVS 0.00
- Stochastic Oscillator
- MYFW 89.15
- CRVS 72.64
About MYFW First Western Financial Inc.
First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).